



Fidson Healthcare Plc RC 267435

Corporate Head Office:
268, Ikorodu Road, Obanikoro,
P.O.Box 7210, Shomolu, Lagos.
Tel: +234 807 700 8888,
+234 01-3429102,
e-mail. info@fidson.com
www.fidson.com

Lagos: 28TH APRIL 2023

FIDSON HEALTHCARE PLC BECOMES THE MARKETING AUTHORISATION HOLDER (MAH) FOR NIGERIA'S FIRST MALARIA VACCINE

On Monday, the 17th of April 2023, the National Agency for Food and Drug Administration and Control (NAFDAC) granted provisional approval for R21 Malaria Vaccine to be marketed in Nigeria.

This approval followed a collaboration between Fidson Healthcare Plc and Serum Institute of India Pvt Limited (SIPL), the manufacturer of the Vaccine. The vaccine is indicated for the prevention of clinical malaria in children from 5 months to 36 months of age. It has been proven in clinical trials to significantly reduce the disease burden and is expected to reduce mortality related to malaria, especially in tropical Africa.

With this development, the investing public is assured of the determination of the Board and Management of Fidson Healthcare Plc to remain the preferred healthcare company that will continue to add value to life with brands that deliver sustainable and profitable growth.

BY ORDER OF THE BOARD

J A ADEBANJO

COMPANY SECRETARY

Board of Directors:

Olusegun S. Adebajo FCA (Chairman)	Olufunmilola O. Ayebae (Mrs.)	Aishratu P. Sadauki (Mrs.) OON	Ekunlufe N. Okoll	Abiola A. Adebayo (Executive)
Dr. Fidolis A. Ayebae (MD/CEO)	Emmanuel E. Imoagene	Dr. Vincent I. Ahonkhai	Olugbenga O. Olayeye (Executive)	Ola E. Ijimakin (Executive)

Factory Address:

Veepae Avenue, Km 38, Lagos-Abeokuta Expressway, Sango Ota, Ogun State, Nigeria.